107966-98-3

Upstream product

• 5367-28-2 5-chloro-2-nitrotoluene 
• 83-42-1 6-chloro-2-nitrotoluene 
• 7443-25-6 dimethyl 2-(4-methoxybenzylidene)malonate 

Downstream Products

• 107966-99-4 [2-(2-amino-5-chlorophenyl)-1-(4-methoxyphenyl)ethyl]propanedioic acid,dimethyl ester 
• 119217-67-3 α-Ethyl-[2-(5-chloro-2-nitrophenyl)-1-(4-methoxyphenyl) ethyl]propanedioic acid, dimethyl ester 
• 111604-67-2 (3R,4S)-7-Chloro-1-(2-dimethylamino-ethyl)-3-ethyl-4-(4-methoxy-phenyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111604-67-2 (3R,4R)-7-Chloro-1-(2-dimethylamino-ethyl)-3-ethyl-4-(4-methoxy-phenyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 138337-22-1 (3S,4R-cis)-3-hydroxy-1-<2-(dimethylamino)ethyl>-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-chloro-2H-1-benzazepin-2-one 
• 138383-37-6 (3R,4S-cis)-3-hydroxy-1-<2-(dimethylamino)ethyl>-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-chloro-2H-1-benzazepin-2-one 
• 111604-68-3 (3R,4S)-3-Allyl-7-chloro-1-(2-dimethylamino-ethyl)-4-(4-methoxy-phenyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111604-68-3 (3S,4S)-3-Allyl-7-chloro-1-(2-dimethylamino-ethyl)-4-(4-methoxy-phenyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111604-66-1 (3S,4S)-7-Chloro-1-(2-dimethylamino-ethyl)-4-(4-methoxy-phenyl)-3-methyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111604-66-1 (3R,4S)-7-Chloro-1-(2-dimethylamino-ethyl)-4-(4-methoxy-phenyl)-3-methyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111604-78-5 7-Chloro-4-(4-methoxy-phenyl)-3-methyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 119217-68-4 α-Ethyl-[2-(5-chloro-2-aminophenyl)-1-(4-methoxyphenyl)ethyl]propanedioic acid, dimethyl ester 
• 138573-36-1 2-Allyl-2-[2-(2-amino-5-chloro-phenyl)-1-(4-methoxy-phenyl)-ethyl]-malonic acid dimethyl ester 
• 111604-79-6 (3S,4R)-7-Chloro-3-ethyl-4-(4-methoxy-phenyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Fluoride-catalyzed Michael addition of nitrotoluenes to activated α, β-unsaturated esters

We have found that in the presence of fluoride ion, nitrotoluenes of type 1 undergo Michael addition to activated α, β-unsaturated esters of type 2 in good to excellent yield (Scheme 1). The generality and limitation of this reaction and its application t

Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones

As part of a program to discover potent antihypertensive analogues of diltiazem (3a), we prepared 1-benzazepin-2-ones (4). Benzazepinones competitively displace radiolabeled diltiazem, and show the same absolute stereochemical preferences at the calcium channel receptor protein. Derivatives of 4 containing a trifluoromethyl substituent in the fused aromatic ring show potent and long-acting antihypertensive activity. Studies of the metabolism of 4 lead to the metabolically stable antihypertensive calcium channel blockers 5a and 5c. Benzazepinone 5a is a longer acting and more potent antihypertensive agent than the second generation diltiazem analogue TA-3090 (3e).

Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site

We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presenc

Benzazepine derivatives

Vasodilating activity is exhibited by compounds having the formula STR1 and pharmaceutically acceptable salts thereof.

Benzazepine derivatives

Vasodilating activity is exhibited by compounds having the formula STR1 and pharmaceutically acceptable salts thereof.

3-substituted benzazepines

Benzazepine derivatives useful, for example, as cardiovascular agents, are disclosed. These compounds have the general formula STR1 and pharmaceutically acceptable salts thereof.